Human Cancer Biology

Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration

Edmund K. Bartlett¹, Patricia A. Fetsch², Armando C. Filie², Andrea Abati², Seth M. Steinberg³, John R. Wunderlich¹, Donald E. White¹, Daniel J. Stephens¹, Francesco M. Marincola⁴, Steven A. Rosenberg¹, and Udai S. Kammula¹

Abstract

Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether there exists a determined pattern in tumor cellular heterogeneity that may guide the development of future targeted immunotherapies.

Experimental Design: From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites. To allow specific tumor cell profiling, we used established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100, MART-1, and tyrosinase. To gain insight into the endogenous host immune response against these tumors, we further characterized tumor cell expression of MHC I and MHC II and, also, the concomitant CD4⁺ and CD8⁺ T-cell infiltrate.

Results: Tumor cell profiling for MDA expression demonstrated an anatomic site-specific pattern of antigen expression that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral metastases. Hierarchical clustering analysis supported that melanoma metastases have a phylogenetically determined, rather than a stochastic, pattern of antigen expression that varies by anatomic site. Furthermore, tyrosinase expression was more frequently lost in metastatic sites outside of the brain and was uniquely correlated with both endogenous CD8⁺ and CD4⁺ T-cell infiltrates.

Conclusion: Site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered in future therapy development and when assessing the responsiveness to antigen-specific immunotherapies. Clin Cancer Res; 20(10); 2607–16. ©2014 AACR.

Introduction

Cancer metastases can demonstrate cellular heterogeneity between synchronous tumors (interlesional heterogeneity) and within individual tumors (intralesional heterogeneity; ref. 1). This phenomenon is thought to be driven by the stochastic genetic instability of tumor cell clones combined with the nonstochastic selective pressures of the host and tumor microenvironment (1–3). Early evidence for metastatic tumor heterogeneity in animal models (4, 5) has been substantiated by more recent high-resolution deep sequencing analyses of human tumors (6). Metastasis heterogeneity, thus, presents a significant obstacle to the current developmental paradigm for highly targeted molecular and immune-based therapeutics for patients with metastatic cancer. Studies of cutaneous melanoma provide a distinctive opportunity to gain further insight into the nature of human metastasis heterogeneity. Melanoma metastases have been shown to have a high mutation frequency (7, 8), diverse phenotype (4, 9), a clinically diffuse dissemination pattern (10), and a unique ability to elicit spontaneous antigen-specific host immune responses (11, 12). As highly targeted immune therapies are currently in development for the treatment of metastatic melanoma, an improved understanding of metastasis heterogeneity is critical to assessing potential tumor susceptibility in future clinical studies.

To allow facile, reproducible, and specific profiling of the tumor cells within individual metastases, we used...
established immunohistochemical methods to perform semiquantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDA), including gp100 (13, 14), MART-1 (13, 14), and tyrosinase (15). These tumor lineage antigens serve as favorable profiling markers given their high expression in normal melanocytes and primary melanoma tumors but heterogeneous expression in metastatic lesions (16–19). T-cell recognition and clearance of MDA-expressing cells (immunediting) has been implicated as a putative mechanism for tumor antigen heterogeneity among melanoma metastases (20–23). To gain insight into the relationship between antigen expression in metastases and endogenous host immune response, we further characterized tumor cell expression of MHC I and II and, also, the concomitant CD4+ and CD8+ T-cell infiltrates within the tumors.

Materials and Methods

Study population

Between May 1, 1995, and August 7, 2012, 3,234 patients with metastatic cutaneous melanoma were evaluated in the Surgery Branch of the National Cancer Institute. A total of 1,514 patients underwent protocol-associated metastatic tumor biopsies to obtain a total of 3,483 specimens; 3,086 of these biopsies were diagnostic for metastatic melanoma and further characterized by an immunohistochemical panel of tumor markers, including gp100, MART-1, tyrosinase, MHC class I, and MHC class II. A total of 2,886 of the evaluable biopsies were fine-needle aspirates (FNA), 303 were frozen sections, and 25 were not specified and thus excluded from the analysis. Biopsies were further considered nonevaluable and removed from the analysis for the following reasons: nondiagnostic for melanoma, absence of quantitative antigen expression data, or medical history that was not consistent with cutaneous melanoma.

All information relating to the biopsies was collected in a prospective fashion beginning in 1995. The site of the biopsy was established from the pathology report and clinical notes. The distinction between subcutaneous, lymph node, and other soft-tissue metastases is often difficult to make clinically. To maintain consistency and accuracy in denoting site of metastases, biopsies from specified lymph node basins (groin, axilla, iliac, intra-abdominal, and cervical) or clinically obvious lymph nodes were classified as lymph node metastases. All other non-nodal soft-tissue lesions were categorized as soft tissue/subcutaneous (ST/SQ) metastases. A site-specific analysis was performed on all sites for which greater than 20 evaluable biopsies were available. Limited sample size for other sites (bone, adrenal, omentum, parotid, kidney, and pancreas) precluded their inclusion in the current analysis.

Tissue procurement

Tumor samples and biopsies were obtained on clinical research protocols approved by the Institutional Review Board and the U.S. Food and Drug Administration. All patients gave informed consent for biopsy and analysis of their tumors in accordance with the Declaration of Helsinki. Tissue samples were prepared using 2 methods. First, multiple radial passage FNAs were performed using a 22- or 23-gauge needle to aspirate in situ lesions or freshly resected tumors. The aspirate was diluted in RPMI-1640 medium (GIBCO BRL) and cytopsins were prepared. Second, samples of surgically resected tumor specimens were prepared by freezing in optimum cutting temperature (OCT) compound (Miles). Frozen tissue was then sectioned and evaluated for the presence of tumor using hematoxylin and eosin staining. Evaluation of antigen expression by FNA has been described previously to correlate highly with antigen expression evaluated by frozen section (14, 24).

Immunohistochemistry

Throughout the duration of the study, all staining was performed by a single cytopathology technician (P.A. Fetsch). Melanoma antigen immunoreactivity of tumor cells in the biopsy specimens was assessed on acetone-fixed cytopsins or frozen tissue sections by using antibodies against gp100 (clone HMB45), MART-1 (clone M2-7C10), and tyrosinase (clone T311). A negative sample control (purified myeloma protein, mouse IgG1 kappa; Organon Teknika Corporation) and positive controls (melanoma cell lines) were performed throughout the study period. A modified avidin/biotin procedure (Vector Laboratories) was performed, with either 3,3-diaminobenzidine or, in the case of highly pigmented samples, 3-amino-9-ethylcarbazole as the chromogen. MHC expression of tumor cells in the biopsy specimens was assessed using antibodies against MHC class I (clone W6/32) and MHC class II (clone 4A12). Lesions were categorized as negative (no positive cells), 1%–25% (one positive cell or more), 25%–50%, 50%–75%, and >75% according to the percentage of cells expressing a given antigen. Lymphocytic
infiltrate in the biopsy specimens was assessed by using antibodies against CD4 and CD8 (Coulter Becton-Dickinson). Infiltrate was graded on a 0 to 3+ scale. All specimens were prospectively assessed by a consistent group of board-certified cytopathologists in the Department of Cytopathology/NIH using established standardized criteria, and the results were serially recorded in a prospectively established database.

**Statistical analysis**

For descriptive analytic purposes, the antigen expression trend for a staining distribution was determined using the slope resulting from a simple linear regression of the percent of tumors with a given expression level versus the category/NIH using established standardized criteria, and the certified cytopathologists in the Department of Cytopathology/NIH (Fig. 1A). The most commonly biopsied sites included soft tissue and subcutaneous (ST/SQ, n = 1,584) followed by lymph nodes (n = 1,015). However, other frequently sampled metastatic sites included lung (n = 125), liver (n = 78), bowel (n = 65), brain (n = 37), and spleen (n = 21).

Initial comparative analysis across all metastatic lesions demonstrated interlesional heterogeneity in MHC and MDA expression ranging from complete absence of antigen to uniformly high expression (>75% of tumor cells) within individual metastases (Fig. 1B). The pattern of staining for MHC I (n = 1,336) and MHC II (n = 1,360) differed significantly (P < 0.0001 by the marginal homogeneity test). Simple linear regression analysis of the percentage of tumors within a given expression level versus the expression level category demonstrated strong inverse trends toward a higher percentage of metastases staining strongly for MHC I (slope = 9.4) and a lower percentage for MHC II (slope = 4.5). The frequency of metastases with complete absence of staining for MHC I and MHC II was also notably different (5% and 28%, respectively; P < 0.0001 by the McNemar test). In contrast to the highly skewed expression for the MHC molecules, the staining for gp100 (n = 3,036), MART (n = 3,047), and tyrosinase (n = 1,598) was found to be more evenly distributed among the metastases (Fig. 1B). Pairwise comparison of the interlesional expression pattern for the 3 MDAs revealed that there was a substantial association between expression levels (P < 0.0001 by the Jonckheere–Terpstra test) but variability among the MDAs was also noted. Tyrosinase expression demonstrated a trend toward lower percentages of stained cells (slope = 1.6), whereas gp100 (slope = 1.5) and MART (slope = 3.2) both trended toward greater frequencies of stained cells. Differences between antigen expression were further illustrated by significant variability in the percentage of metastases with complete absence of staining for MART, gp100, and TYR (16%, 21%, 28% respectively; P < 0.0001 for each pairwise comparison of the 3 MDAs using the McNemar test).

To better define the relationship between antigen markers within individual metastases, we next determined the concordance and discordance frequency between MHC I and II expression and, also, between the 3 MDAs. Concordant expression between 2 markers was defined as having ≤25% of the tumor cells within a single lesion differ in their expression of the 2 markers. Conversely, discordant expression was defined as having >25% of the cells differ in expression. Coexpression plots revealed that MHC I and MHC II expression (n = 1,319) were considered statistically significant whereas 0.005 < P < 0.05 would be considered a strong trend.

**Results**

**Human melanoma metastases demonstrate interlesional heterogeneity in MDA and MHC expression**

From a cohort of 1,514 patients with metastatic melanoma, biopsies were procured over a 17-year period from 3,086 metastatic tumors involving various anatomic sites (Fig. 1A).
concordant in 56% of lesions (Fig. 1C). Metastases with low frequencies of MHC I–positive cells consistently possessed low frequencies of MHC II–positive cells and lesions with a high frequency of MHC II–positive cells concomitantly expressed a high degree of MHC I staining. However, consistent with their inversely skewed expression pattern, MHC II expression in metastases was rarely seen in the absence of MHC I (1% of tumors), with the majority of discordant lesions expressing higher MHC class I when compared with MHC II (43% of tumors). Next, we compared the synchronous expression of the MDAs within individual metastases \( (n = 1,561; \text{Fig. 1D}) \). Coexpression plots revealed a strong linear association between each of the antigen pairs (all 3 comparisons: \( P < 0.0001 \) by the Jonckheere–Terpstra test). These strong concordant relationships were not surprising given that gp100, MART, and tyrosinase expression share a common transcriptional pathway involving the microphthalmia-associated transcription factor (MITF; refs. 29, 30). However, we did observe metastases with discordant antigen expression: 25% in MART versus gp100, 34% in gp100 versus tyrosinase, and 36% in MART versus tyrosinase. The lesions with discordant MART and gp100 expression were evenly distributed between having high MART and low gp100 (12%) and low MART and high gp100 expression (13%). In contrast, the coexpression plots for tyrosinase revealed that the discordant lesions demonstrated absence of tyrosinase twice as often as gp100 (23% vs. 11%) and MART (24% vs. 12%). Cumulatively, these findings demonstrated that melanoma metastases have significant interlesional heterogeneity in MHC and MDA expression with discordant MDA expression in approximately one third of lesions and more frequent absence of tyrosinase expression when compared with MART and gp100.
MDA and MHC II expression in metastases demonstrate a site-specific pattern

To determine whether the observed tumor heterogeneity varied by location of the metastases in the host, we next compared the MDA and MHC expression pattern in lesions from the 7 most frequently biopsied anatomic sites (ST/SQ, lymph node, lung, liver, bowel, brain, and spleen; Fig. 2A). Analysis for each of the MDAs revealed site-specific antigen variability (gp100: \( P < 0.0001 \), MART: \( P < 0.0001 \), tyrosinase: \( P = 0.0057 \)). Trend analysis of the antigen distribution patterns was used to rank the expression associated with individual anatomic sites (Fig. 2B). Brain metastases consistently demonstrated high expression of each of the MDAs based upon positive skewed antigen trends (gp100: slope = +5.8; MART: slope = +8.6; tyrosinase: slope = +6.5). In contrast, liver and lung metastases demonstrated lower expression of each of the MDAs with consistently negative antigen trends (gp100: slope = −1.9 and −4.7; MART: slope = −1.3 and −1.9; tyrosinase: slope = −10.0 and −6.6, for liver and lung, respectively). Individual pairwise comparison of liver, lung, and bowel metastases further established that each of these sites had lower MDA expression than brain metastases (\( P < 0.05 \); Supplementary Table S1). Antigen expression was more variable for ST/SQ and lymph node metastases, which demonstrated a trend toward higher percentages of stained cells for gp100 (slope = +1.7 and +1.9, respectively) and MART (slope = +3.5 and +3.7, respectively) but lower expression of tyrosinase (slope = −1.4 and −1.9, respectively). Individual pairwise comparison of ST/SQ and lymph node metastases demonstrated that each of these sites had higher gp100 and MART expression than liver and lung metastases (\( P < 0.05 \); Supplementary Table S1). Tumor cell expression of MHC class I was high across all sites (slope range: +6.8 to +11.7) with no significant site-specific variability (\( P = 0.41 \)). MHC II–expressing tumor cells were less commonly found in the metastases; however, its staining profile did vary by anatomic site (\( P < 0.0001 \)). Liver metastases demonstrated the highest expression of MHC II (slope = +1.2), whereas ST/SQ (slope = −5.9) and bowel (slope = −6.7) lesions showed the lowest expression. From these findings, we concluded that MDA and MHC II expression in metastases varied significantly by anatomic site.
MDA expression in melanoma metastases cluster in a site-specific phylogenetic pattern

We next investigated whether the site-specific antigen heterogeneity in the metastases had a phylogenetically determined, rather than a stochastic, pattern. Hierarchical clustering of the individual metastatic sites was performed on the basis of their antigen expression profiles to determine whether there were antigenic similarities between anatomic sites (Fig. 3A; Supplementary Table S2). Dendrogram branch analyses for each of the MDAs revealed that the brain expression of MART, gp100, and tyrosinase shared a similar pattern and clustered as a main group (Fig. 3B). gp100; MART; T, TYR. C, ranking of antigen expression trend by metastatic cluster site. Clustered sites are defined as brain, ST/nodal (ST/SQ and lymph node, LN), and visceral (lung and liver). The ordered results are presented from high positive to low or negative slope for display purposes and are not tested for this trend as it was not a prespecified hypothesis. The $P$ values indicate the probability that no variability exists across the clustered sites as determined by the Kruskal–Wallis test.

Figure 3. MDA expression in melanoma metastases cluster in a site-specific phylogenetic pattern. A, dendrogram branch analyses based upon expression of individual MDAs in metastases of differing anatomic sites. B, dendrogram branch analyses of cumulative MDA expression in metastases. Arrows indicate the divergence of tyrosinase (TYR) expression from the clustering of gp100 and MART. gp, gp100; M, MART; T, TYR. C, ranking of antigen expression trend by metastatic cluster site. Clustered sites are defined as brain, ST/nodal (ST/SQ and lymph node, LN), and visceral (lung and liver). The ordered results are presented from high positive to low or negative slope for display purposes and are not tested for this trend as it was not a prespecified hypothesis. The $P$ values indicate the probability that no variability exists across the clustered sites as determined by the Kruskal–Wallis test.

Metastatic site cluster

Expression vs. cluster

$P$ value

<table>
<thead>
<tr>
<th>MDA</th>
<th>Expression vs. cluster</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>gp100</td>
<td>Brain (36)</td>
<td>ST/nodal (2,558)</td>
</tr>
<tr>
<td></td>
<td>$&lt;0.0001$</td>
<td></td>
</tr>
<tr>
<td>MART</td>
<td>Brain (36)</td>
<td>ST/nodal (2,564)</td>
</tr>
<tr>
<td></td>
<td>$&lt;0.0001$</td>
<td></td>
</tr>
<tr>
<td>TYR</td>
<td>Brain (26)</td>
<td>ST/nodal (1,375)</td>
</tr>
<tr>
<td></td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>MHC I</td>
<td>Brain (9)</td>
<td>Visceral (147)</td>
</tr>
<tr>
<td></td>
<td>N.S.</td>
<td></td>
</tr>
<tr>
<td>MHC II</td>
<td>Visceral (145)</td>
<td>ST/nodal (1,062)</td>
</tr>
<tr>
<td></td>
<td>$&lt;0.0001$</td>
<td></td>
</tr>
</tbody>
</table>

Antigen expression trend (slope of linear regression)

-10 -5 0 5 10 15

Visceral (145)

ST/nodal (1,062)

$P < 0.0001$.
the individual metastatic site clusters. Consistent with their independent clustering, brain metastases demonstrated positive antigen trends for all 3 MDAs, which were higher in magnitude than both the soft tissue/nodal and visceral metastases. In turn, soft tissue/nodal tumors had higher MDA expression than visceral tumors, which had negative antigen trends for all MDAs. Consistent with their independent clustering pattern by dendrogram analysis, the tyrosinase expression in soft tissue/nodal metastases had a negative antigen trend that was not statistically different from visceral metastases by pairwise comparison ($P = 0.16$ by the Cochran–Armitage test; Supplementary Table S4). In sum, these findings supported a nonstochastic stratified pattern of MDA expression that was highest in brain metastases, intermediate in soft tissue/nodal metastases, and lowest in visceral metastases. Notably, the expression profile for gp100 and MART were similar, but tyrosinase antigen expression in sites outside of the brain was distinctly lower than the other 2 antigens.

**Tyrosinase is uniquely correlated with both CD4$^+$ and CD8$^+$ T-cell infiltrates**

To explore whether the observed loss and variation in tyrosinase expression may be a result of host immune targeting, we next sought to define the relationship between antigen expression with CD8$^+$ and CD4$^+$ T-cell infiltration. Lymphocytic infiltrate was categorically scored from 0 (no infiltrate) to 3+ (high infiltrate). The antigen expression trend for each level of CD8$^+$ and CD4$^+$ lymphocytic infiltrate was determined (Supplementary Fig. S2) and used to rank the expression associated with each degree of T-cell infiltration. On the basis of overall expression levels, there were strong ordered associations between CD8$^+$ T-cell infiltration and MART, tyrosinase, and MHC II expression in the metastases (each $r = 1.00; P < 0.0001$; Fig. 4A).

![Diagram showing correlation between antigen expression trend and degree of CD8, CD4, MART, and MHC I/II infiltration](chart.png)

**Figure 4.** Tyrosinase (TYR) is uniquely correlated with both CD4$^+$ and CD8$^+$ T-cell infiltrates. A, correlation between antigen expression trend and degree of CD8 infiltrate ($y$-axis). B, correlation between antigen expression trend and degree of CD4 infiltrate ($y$-axis). Blue (CD8) and green (CD4) coding of bars indicates negative antigen trends. Results presented are the Spearman correlation coefficient and a $P$ value for a test of whether $r = 0$. 
Interestingly, tyrosinase was the only marker that demonstrated a strong association with CD4+ T-cell infiltration ($\chi^2 = 1.00; P < 0.0001$; Fig. 4B). We concluded that the exclusive correlation of tyrosinase expression with both CD8+ and CD4+ T-cell infiltrates could be consistent with immunoediting as the mechanism for the selective loss of tyrosinase among the metastases.

Discussion

From the prospective analyses of more than 3,000 human melanoma metastases, we demonstrate an anatomic site-specific pattern of melanocyte differentiation antigen expression with the highest levels seen in brain, intermediate levels in soft tissues/lymph nodes, and lowest levels in visceral metastases. Although heterogeneity of metastases has been well-described (16–19), to our knowledge, a determined pattern of tumor antigen expression based upon anatomic site of metastasis has not been previously demonstrated in humans. Conceptually, metastatic heterogeneity is thought to result from stochastic genetic and epigenetic events under selective pressure exerted by the host and tumor microenvironment. This theory is based upon our understanding of the metastatic process as described originally by Paget’s “seed and soil” hypothesis (31) and refined by work from Fidler, and others, in animal models (1, 32). Site-specific interactions between the “seed” and “soil” could partially explain the tumor heterogeneity at different anatomic sites found in our study. In fact, the observation that brain metastases have the highest MDA expression is particularly consistent with early studies in nude mice, which demonstrated that melanoma brain metastases were uniformly pigmented compared with the variable pigmentation of tumors observed at other metastatic sites (4). In contrast to these immunodeficient animal models, here we sought to explore the interplay of the immune response with metastatic heterogeneity. Immunoediting, whereby antigen-expressing cells are selectively eliminated or antigens are reversibly lost as an escape mechanism, has been demonstrated in several animal models (20–23, 33, 34). However, the in vivo association of specific tumor antigens and MHC expression with natural endogenous immune responses has not been clearly demonstrated in humans. In a large cohort of melanoma metastases, we observed a significant association between tumor expression of MHC II (not MHC I) and CD8+ infiltrate. We hypothesize that this counterintuitive finding suggests an important role for CD4+ “T-helper cell interaction with MHC II in the tumor microenvironment. This CD4+ “help” may facilitate CD8+ immune responses against endogenous tumor antigens. Although direct evidence for this phenomenon is beyond the observational aspect of this study, CD4 help has been demonstrated in numerous viral and tumor models (35, 36). We believe that this observation in human tumors provides a biologically relevant association between these variables that may be further explored in future therapies involving CD4+ adoptive immunotherapy or vaccine efforts.

We also report that tyrosinase expression is absent twice as often in melanoma metastases compared with gp100 and MART. Furthermore, the discordant and selective loss of tyrosinase was uniquely correlated with the levels of both endogenous CD8+ and CD4+ infiltrating T cells, suggesting that tyrosinase expression in metastases may be naturally and selectively edited by antigen-specific T cells. MART expression, although correlated with CD8+, was not correlated with CD4+, possibly suggesting the importance of a polyclonal T-cell population in immunoediting. It is interesting that in our antigen expression cluster analysis, brain metastases demonstrated no variation in tyrosinase expression when compared with the profile of the other antigens. This finding would suggest that the process driving differential tyrosinase loss is mitigated within the brain, potentially consistent with the immunoprivileged status of the central nervous system. Interestingly, experimental evidence in animal models of melanoma has established immunoediting as the mechanism behind the preferential and site-specific loss of tyrosinase compared with other MDAs. Our findings are remarkably consistent with those reported in a double-transgenic MT-ret/AAD mouse model, which recapitulates the natural history of human melanoma through the spontaneous development of cutaneous and visceral tumors (37). The authors reported that tyrosinase and tyrosinase-related protein 2 (TRP2) expression were markedly reduced in both liver and lung tumors when compared with cutaneous tumors. Furthermore, they noted a concomitant natural induction of CD8+ T cells specific for both tyrosinase and TRP2, suggesting that the visceral tumors, rather than the cutaneous tumors, were preferentially targeted to immunoedit the antigen-specific T cells. In another murine study, a vaccine targeting normal melanocytes induced polyclonal T-cell responses that resulted in the generation of B16 melanoma escape variants which grew aggressively in vivo, became amelanotic, and preferentially lost expression of tyrosinase and TRP2 but maintained expression of other melanoma-associated antigens, such as gp100 (38), a finding that directly parallels our human observations.

Collectively, our current profiling of human metastasis antigen expression and immune infiltrate provides compelling evidence for a nonstochastic distribution of antigen expression based upon anatomic site. Although our study focused on the well-described MDAs, these results may warrant future investigation into the site-specific expression of a wide variety of antigens, including mutated antigens and cancer-testis antigens, as well as the intratumoral heterogeneity of these antigens in individual metastases. The broad implications of our study would further support that clinicians using immunotherapeutics—and potentially other targeted therapies—should consider that target assessment within metastasis is highly contingent on the anatomic site of biopsy. Ideally, biopsies should be obtained from the sites of disease anticipated to be most influential on the eventual outcome of the patient. Furthermore, tracking antigen loss in tumors should be performed on the same lesion to avoid the confounding variable of...
interlesional heterogeneity. In sum, the cumulative findings in this report support that future clinical effort using targeted immune therapies must account for site-specific heterogeneity when assessing their use and impact on metastases.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions


Development of methodology: P.A. Fetsch, F.M. Marincola, U.S. Kammula

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.J. Wunderlich, D.J. Stephens, S.A. Rosenberg, U.S. Kammula

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.K. Bartlett, S.M. Steinberg, D.E. White, D.J. Stephens, F.M. Marincola, U.S. Kammula

References

Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-2690

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/03/19/1078-0432.CCR-13-2690.DC1

Cited articles
This article cites 35 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/10/2607.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/20/10/2607.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.